175 related articles for article (PubMed ID: 20167205)
21. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study.
Bendfeldt K; Kuster P; Traud S; Egger H; Winklhofer S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Matthews PM; Nichols TE; Radue EW; Borgwardt SJ
Neuroimage; 2009 Mar; 45(1):60-7. PubMed ID: 19013533
[TBL] [Abstract][Full Text] [Related]
22. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
24. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
Filippi M; Rocca MA; Camesasca F; Cook S; O'Connor P; Arnason BG; Kappos L; Goodin D; Jeffery D; Hartung HP; Comi G; Wolinsky JS; Bogumil T; Pohl C; Beckmann K; Sandbrink R; Croze E; Brown C; Desimone TM; Arnold DL; Cutter G; Knappertz V
Neurology; 2011 Apr; 76(14):1222-8. PubMed ID: 21464426
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
Galetta SL; Markowitz C; Lee AG
Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
[TBL] [Abstract][Full Text] [Related]
26. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
28. Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis.
Bendfeldt K; Blumhagen JO; Egger H; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Hirsch J; Kappos L; Nichols TE; Radue EW; Borgwardt SJ
Hum Brain Mapp; 2010 Oct; 31(10):1542-55. PubMed ID: 20108225
[TBL] [Abstract][Full Text] [Related]
29. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
Bastianello S; Giugni E; Amato MP; Tola MR; Trojano M; Galletti S; Luccichenti G; Quarantelli M; Picconi O; Patti F;
BMC Neurol; 2011 Oct; 11():125. PubMed ID: 21999142
[TBL] [Abstract][Full Text] [Related]
30. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
31. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
32. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
33. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
[TBL] [Abstract][Full Text] [Related]
34. Considerations in the treatment of relapsing-remitting multiple sclerosis.
Calabresi PA
Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.
De Stefano N; Giorgio A; Gentile G; Stromillo ML; Cortese R; Gasperini C; Visconti A; Sormani MP; Battaglini M
Ann Clin Transl Neurol; 2021 Mar; 8(3):623-630. PubMed ID: 33534940
[TBL] [Abstract][Full Text] [Related]
36. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
37. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
[TBL] [Abstract][Full Text] [Related]
38. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
39. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis.
Calabrese M; Mattisi I; Rinaldi F; Favaretto A; Atzori M; Bernardi V; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P
J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):401-4. PubMed ID: 19965849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
